fda semaglutide warning november 2025 From a new Perspective by Amanda Banks, MD: On February 5, 2026, Hims & Hers, an online health and wellness platform, announced its intention to sell compounded oral semaglutide, a glucagon-like peptide-1 ( FDA Approves Semaglutide to Reduce

With similar capabilities now offered by D2C healthcare companies like Hims, Noom, Ro, and WeightWatchers, differentiation will hinge on cost and accessible coaching/supportespecially guidance through untested areas like microdosing weight loss drugs

Despite decades of public health messaging urging Americans to eat fewer calories , major trials have failed to demonstrate that calorie restriction meaningfully reduces cardiovascular disease, cancer, or mortality

Shown to tighten skin, rather than leaving skin loose around the treated area

doi:10.18632/aging.100230 273

You may need a higher dose of the medication to get significant results

Norepinephrine content and adrenoceptor function in the bladder of cats with feline interstitial cystitis